No Data
No Data
Repare Therapeutics Inc. (NASDAQ:RPTX) Is Definitely on the Radar of Institutional Investors Who Own 36% of the Company
Express News | Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients With Metastatic Gynecologic Cancers
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Data and Market Potential
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Repare Therapeutics Inc. (NASDAQ:RPTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Repare Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1/2 Cancer Trial Data at the European Society of Medical Oncology Congress (ESMO).
No Data
No Data